Unraveling the architecture of poxvirus cores

A recent re-emergence and outbreak of Mpox brought poxviruses back as a public health threat, underlining an important knowledge gap at their core.

Dexcom CEO talks Stelo sensor launch, OTC strategy

Dexcom CEO Kevin Sayer shared new data on the company’s first over-the-counter glucose sensor at the J.P. Morgan Healthcare Conference on Monday. Stelo, which is

January 15, 2025

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia | Psychedelic Invest

SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing

December 18, 2024

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Adding a mutation-specific targeted drug to osimertinib (Tagrisso) substantially increased the objective response rate (ORR) in newly diagnosed EGFR-mutant, MET-aberrant non-small cell lung cancer (NSCLC),

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.